Physician profile
Amber L Shutter
NPI 1013378827
$2,176.24
in general payments reported to CMS, 2019-2025
14 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $294 · 2024: $505 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.28 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $416.14 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $292.65 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $276.27 | 2025 | Auvelity |
| Alkermes, INC. | $221.26 | 2024-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $144.58 | 2024-2025 | Uzedy |
| Neurocrine Biosciences, INC. | $115.29 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.80 | 2024-2025 | Caplyta |
| Indivior INC. | $59.58 | 2024 | Perseris |
| Bioxcel Therapeutics, INC. | $23.75 | 2024 | Igalmi |
| Lundbeck LLC | $17.24 | 2024 | Rexulti |
| Luye Pharma (USA) LTD. | $15.43 | 2025 | Erzofri Extended-Release |
| Takeda Pharmaceuticals U.S.A., INC. | $15.28 | 2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $14.69 | 2025 | Invega |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Shutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.